First-line treatment of chronic heart failure (CHF) usually involves a beta blocker, an angiotensin-converting enzyme (ACE) inhibitor, and  an oral diuretic. Second- or third-line treatments are often needed to better manage the disease. Physicians have numerous drug classes to choose from, most of which consist of drug options. The CHF market is heavily genericized, as such physician practice is minimally impacted by pricing pressures. The CHF Treatment Algorithm offers insight into prescribing patterns in this multi-layered treatment landscape where few branded agents jostle for patient share in a crowded sector.  That said, small patient shares for such a prevalent indication can translate into significant commercial positions.

Author(s): Graeme Green, PhD, MSc

Related Reports

Heart Failure - Geographic Focus: China - Heart Failure | China In-Depth | China

Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population...

View Details

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacolog...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Preserved Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophys...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF)...

View Details